<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chronic rhinosinusitis without nasal polyposis: Management and prognosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chronic rhinosinusitis without nasal polyposis: Management and prognosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Chronic rhinosinusitis without nasal polyposis: Management and prognosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Matthew A Rank, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric H Holbrook, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anju T Peters, MD, MSCI</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel G Deschler, MD, FACS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna M Feldweg, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 12, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2140146684"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Chronic rhinosinusitis without nasal polyposis (CRSsNP) is characterized by 12 weeks or more of at least two of four cardinal symptoms: nasal obstruction, anterior or posterior nasal discharge, reduction or loss of smell, and facial pain/pressure/fullness. In addition, there must be objective evidence of mucosal inflammation, either by direct visualization or on an imaging study (usually sinus computed tomography [CT] scan). The diagnosis of CRS is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7528.html" rel="external">"Chronic rhinosinusitis: Clinical manifestations, pathophysiology, and diagnosis"</a>.)</p><p>Chronic rhinosinusitis <strong>without</strong> nasal polyposis is abbreviated in the medical literature as CRSsNP ("s" for "sans" [French], meaning "without"). CRSsNP is the most common subtype of CRS, representing approximately 70 percent of all CRS patients. Other subtypes include chronic rhinosinusitis <strong>with</strong> nasal polyposis (CRSwNP) and allergic fungal rhinosinusitis (AFRS). It is important to distinguish these subtypes when considering management options. Information on how to manage the other subtypes is provided separately. (See  <a class="medical medical_review" href="/z/d/html/121195.html" rel="external">"Chronic rhinosinusitis with nasal polyposis: Management and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/101017.html" rel="external">"Allergic fungal rhinosinusitis"</a>.)</p><p class="headingAnchor" id="H4086243587"><span class="h1">GOALS OF THERAPY</span><span class="headingEndMark"> — </span>People with CRSsNP experience a significant negative impact on quality of life (QoL). The primary goal of therapy is to improve disease-related QoL by controlling symptoms. Modern trial designs generally attempt to capture both subjective symptom control and objective measures of mucosal disease (eg, nasal endoscopy or imaging scores), although symptom control is the most important outcome to patients [<a href="#rid1">1</a>]. Most patients with CRSsNP cannot be cured but can achieve varying degrees of control of symptoms with long-term management.</p><p>It is also helpful to individualize goals with each patient, as some may value specific outcomes over others. As an example, one patient may have a strong preference for restoring a sense of smell if olfaction is important for their occupation, whereas another may wish to avoid use of antibiotics or oral glucocorticoids. However, educating the patient of the chronic nature of the disease and setting realistic expectations are important.</p><p>In patients with comorbid lower airway diseases such as asthma, chronic obstructive pulmonary disease (COPD), or bronchiectasis, another goal of medical therapy for CRSsNP is improved control of lower respiratory disease. (See  <a class="medical medical_review" href="/z/d/html/7536.html" rel="external">"Relationships between rhinosinusitis and asthma"</a>.)</p><p>The approach outlined in this topic is consistent with published guidelines, particularly the 2021 International Consensus on Allergy and Rhinology-Rhinosinusitis (ICAR-RS) and the European Position Paper on Rhinosinusitis and Nasal Polyps 2020 (EPOS2020) [<a href="#rid2">2,3</a>]. (See <a class="local">'Society guideline links'</a> below.) </p><p class="headingAnchor" id="H254413073"><span class="h1">REFERRAL</span><span class="headingEndMark"> — </span>Initial diagnosis and management of CRSsNP can begin with the generalist. However, when the diagnosis or subtype of CRS is uncertain, or if a patient does not benefit from initial therapy, referral to a specialist is appropriate.</p><p class="bulletIndent1"><span class="glyph">●</span>Otolaryngology specialists can help clarify a CRS diagnosis with nasal endoscopy and distinguish CRS subtypes (CRSsNP, chronic rhinosinusitis with nasal polyposis [CRSwNP], allergic fungal rhinosinusitis [AFRS]). They can obtain and interpret sinus images to identify complicating features. This includes addressing rare complications of sinusitis. Otolaryngology specialists can also obtain cultures from purulent material to guide treatment decisions and can perform sinus surgery. (See <a class="local">'Functional endoscopic sinus surgery'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Allergy/immunology specialists can help identify and manage contributing factors including environmental factors (allergens, environmental tobacco smoke), comorbid airway diseases (asthma, chronic obstructive pulmonary disease [COPD], bronchiectasis), and immunodeficiency disorders (such as common variable immune deficiency or specific antibody deficiency).</p><p></p><p class="headingAnchor" id="H2402782702"><span class="h1">INITIAL INTERVENTIONS FOR ALL PATIENTS</span><span class="headingEndMark"> — </span>In all patients, we initially ensure that there are no danger signs to suggest complications or other conditions that can mimic aspects of CRSsNP. We then begin treatment with an intranasal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> spray or irrigation, an intranasal corticosteroid (INCS), or both for at least two months, as improvement is often gradual [<a href="#rid4">4</a>]. When saline and an INCS are used together, the saline should be used first to clear mucous and optimize mucosal absorption of the INCS. Once the saline has drained completely, patients can apply the INCS.</p><p class="headingAnchor" id="H3127025507"><span class="h2">Assess for danger signs</span><span class="headingEndMark"> — </span>A small minority of patients may develop complications of rhinosinusitis, such as expansion of infection/inflammation to involve the orbit or other structures. Specific complications include orbital involvement, mucocele formation, cavernous vein thrombosis, and frontal sinus erosion (Pott's puffy tumor) [<a href="#rid5">5-7</a>]. The following symptoms and signs require immediate evaluation:</p><p class="bulletIndent1"><span class="glyph">●</span>High fever</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe headache or meningeal signs</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Significant or recurrent epistaxis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Orbital signs and symptoms (preseptal or orbital cellulitis, enophthalmos, epiphora, diplopia, proptosis, visual loss, or optic neuropathy)</p><p></p><p>If any of these signs or symptoms are present, urgent involvement of an otolaryngologist/head and neck surgeon, ophthalmologist, and/or neurosurgeon is indicated.</p><p class="headingAnchor" id="H3296007932"><span class="h2">Saline</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">Saline</a> irrigations thin and flush out mucus and inflammatory debris, reduce nasal irritants and allergens, and improve mucociliary function. Patients can perform irrigations as needed, which is usually one to three times daily. Saline can be delivered as a spray or high-volume rinse (60 to 240 mL) [<a href="#rid2">2</a>]. Larger-volume irrigations are more effective than nasal sprays [<a href="#rid8">8,9</a>]. Therefore, we favor a high-volume (240 mL) isotonic (0.9%) saline rinse as the first choice for most patients. To make the saline solution, which also contains baking soda to normalize pH [<a href="#rid8">8</a>], patients can buy commercially prepared packets or make their own solutions, and a patient handout is available  (<a class="graphic graphic_table graphicRef71059" href="/z/d/graphic/71059.html" rel="external">table 1</a>). (See  <a class="medical medical_basics" href="/z/d/html/86630.html" rel="external">"Patient education: How to rinse out your nose with salt water (The Basics)"</a>.)</p><p>Either isotonic <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> or hypertonic saline (usually 3%) can be used. Hypertonic saline, which theoretically draws fluid out of the nasal mucosa, may provide slightly better symptom improvement [<a href="#rid9">9-11</a>] but often causes more nasal irritation [<a href="#rid2">2,12</a>]. Similarly, water or hypotonic saline should be avoided because they can be irritating. Nasal saline irrigation is well tolerated by most adults, although children may not be able to perform it properly. Most complaints regarding use are related to nasal drainage after irrigation and Eustachian tube obstruction or irritation. Eustachian tube complaints can be reduced by instructing patients to relax the mouth and throat and allow irrigation to pass out through the other nostril, as well as into the oropharynx and out the mouth. In addition, avoiding nose blowing for approximately 15 minutes after irrigation will decrease the potential for auto-insufflating the Eustachian tubes with the saline solution. We advise patients to wait until the saline has completely drained before using the INCS so that the medication is not diluted.</p><p>Several devices for high-volume <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> rinses are commercially available. The most common are squeeze bottles and neti pots. Patients should clean the device they are using for the rinse to avoid risk of bacterial contamination [<a href="#rid13">13</a>]. In our experience, patients are often unaware of this recommendation. Periodic microwaving and device replacement, along with use of distilled or boiled water to prepare the rinse, are ways to reduce contamination risk. Transmission of life-threatening infections through nonsterilized tap water has occurred, as discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/7526.html" rel="external">"Pharmacotherapy of allergic rhinitis", section on 'Nasal saline'</a>.)</p><p><a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">Saline</a> nasal sprays can be used instead of irrigations for patients who do not want to perform irrigations or find them uncomfortable.</p><p class="headingAnchor" id="H3386506850"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>Using <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> is likely to improve symptoms and quality of life (QoL) with a small-to-moderate effect size, based on systematic reviews [<a href="#rid2">2,8</a>]. Studies allowing for a definitive recommendation of spray versus high-volume saline rinse specifically for CRSsNP are lacking. In the International Consensus on Allergy and Rhinology-Rhinosinusitis (ICAR-RS) guideline, high-volume (&gt;60 mL) rinses are favored, whereas, in the European guideline on Rhinosinusitis and Nasal Polyps 2020 (EPOS2020), sprays and rinses are considered together [<a href="#rid2">2,3</a>].</p><p class="headingAnchor" id="H2729482997"><span class="h3">Additives</span><span class="headingEndMark"> — </span>Adding substances to <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> rinse solutions, such as xylitol (proposed natural antimicrobial properties), alkalol (contains herbal antiseptics), or baby shampoo [<a href="#rid14">14</a>], may benefit some individuals but is not clearly supported by studies. The risks of their use should be weighed against the limited evidence for efficacy.</p><p class="headingAnchor" id="H145548943"><span class="h2">Intranasal corticosteroids</span><span class="headingEndMark"> — </span>In keeping with guidelines and consensus statements, we recommend topical INCS as first-line pharmacotherapy for CRSsNP [<a href="#rid2">2,3,15</a>]. We typically start with an INCS delivered via a nasal spray, many of which are available without a prescription  (<a class="graphic graphic_table graphicRef55833" href="/z/d/graphic/55833.html" rel="external">table 2</a>). Other delivery systems including addition of INCS to <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> irrigations [<a href="#rid16">16</a>], drops that are applied directly into the nares, exhalation delivery systems [<a href="#rid17">17,18</a>], and nebulizations [<a href="#rid19">19</a>]. A detailed discussion of the other delivery systems for INCS is found separately. (See  <a class="medical medical_review" href="/z/d/html/121195.html" rel="external">"Chronic rhinosinusitis with nasal polyposis: Management and prognosis", section on 'Intranasal corticosteroids'</a>.)</p><p>The ability of different delivery systems to introduce medications into the paranasal sinuses is dependent on several factors, including whether the patient has had previous sinus surgery, the degree of mucosal edema, and the volume and pressure generated by the delivery system [<a href="#rid20">20</a>]. If patients have not had previous sinus surgery, INCS delivered by nasal sprays are unlikely to actually penetrate the sinus cavities, but they are still beneficial by reducing intranasal mucus production and mucosal edema at the outflow tracts of the various sinuses, thus improving drainage. In patients who have had surgery, solutions from sprays, but more likely irrigations, are sometimes able to enter the sinus cavities.</p><p>Our approach to using INCS is described here as definitive studies comparing different delivery systems in patients with CRSsNP are lacking:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients who have not had prior sinus surgery, we suggest nasal sprays as the first option. We ensure that the patient understands proper technique and the importance of using the sprays every day to achieve the best treatment outcome.</p><p></p><p class="bulletIndent1">To use an INCS spray properly, patients should tilt the head slightly forward, aim away from the septum, and avoid taking vigorous sniffs as the medicine is dispensed (so that it stays in the nasal passages and is not pulled down the throat)  (<a class="graphic graphic_figure graphicRef141563" href="/z/d/graphic/141563.html" rel="external">figure 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who had previous sinus surgery or have not responded to INCS sprays used properly and consistently, we suggest a different delivery option. One option is to use glucocorticoid solutions designed for asthma nebulizers (eg, <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">budesonide</a> ampules, 0.5 mg/2 mL) mixed into a high-volume (60 to 240 mL) <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> rinse, one or two times per day. There is less information about rinsing with glucocorticoids other than budesonide, but other formulations could be considered using dose-equivalent ranges, and several preparations of glucocorticoid "nasal drops" are available worldwide [<a href="#rid21">21</a>]. If an exhalation delivery system or nasal nebulizer is chosen, patients should follow manufacturers' instructions.</p><p></p><p class="headingAnchor" id="H2469310595"><span class="h3">Safety and efficacy</span><span class="headingEndMark"> — </span>INCS are unlikely to be associated with systemic adverse effects and are generally well tolerated and accepted by most patients [<a href="#rid22">22</a>]. They are likely to result in small-to-moderate improvements in symptoms and QoL, although studies of INCS delivered by simple nasal spray are mixed [<a href="#rid2">2</a>]. If the patient has not experienced benefit with a spray, therapy can be changed to glucocorticoid irrigations in a high-volume <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> rinse [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H1347135856"><span class="h2">Address contributing factors</span><span class="headingEndMark"> — </span>Other initial considerations include potential management of allergic and irritant triggers, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Allergic rhinitis should be suspected in patients with prominent sneezing or nasal or ocular pruritus. Additional therapies that may be helpful in patients with allergic rhinitis include nonsedating antihistamines, intranasal antihistamines, and allergen immunotherapy. (See  <a class="medical medical_review" href="/z/d/html/7525.html" rel="external">"Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/530.html" rel="external">"Allergen avoidance in the treatment of asthma and allergic rhinitis"</a> and  <a class="medical medical_review" href="/z/d/html/361.html" rel="external">"Subcutaneous immunotherapy (SCIT) for allergic rhinoconjunctivitis and asthma: Indications and efficacy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tobacco smoking or secondhand exposure can worsen the symptoms of CRS [<a href="#rid23">23</a>]. Smoking cessation should be addressed. (see  <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults"</a> and  <a class="medical medical_review" href="/z/d/html/16635.html" rel="external">"Pharmacotherapy for smoking cessation in adults"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Primary or secondary immunodeficiency should be considered in patients with a history of pneumonia (one or more) and recurrent episodes of sinusitis requiring antibiotics. The most common type of immunodeficiency associated with CRSsNP are antibody defects, including specific antibody deficiency and common variable immunodeficiency. (See  <a class="medical medical_review" href="/z/d/html/3914.html" rel="external">"Primary humoral immunodeficiencies: An overview", section on 'Presentation of humoral immunodeficiency'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gastroesophageal reflux disease or laryngopharyngeal reflux disease may contribute to refractory CRS. Reflux therapy may be considered in those with reflux and CRS, but use of proton pump inhibitors (PPIs) is not recommended specifically for the treatment of CRS [<a href="#rid24">24</a>]. (See  <a class="medical medical_review" href="/z/d/html/2258.html" rel="external">"Medical management of gastroesophageal reflux disease in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6852.html" rel="external">"Laryngopharyngeal reflux in adults: Evaluation, diagnosis, and management"</a>.)</p><p></p><p class="headingAnchor" id="H534004582"><span class="h1">MONITORING</span><span class="headingEndMark"> — </span>Upon initiation of treatment, patients should be monitored at regular intervals. We usually ask patients to return three months after initiation of therapy and then every three to six months thereafter until symptoms are adequately managed. At each visit, we assess sinonasal symptoms and quality of life (QoL), perform a nasal exam (endoscopic if available), and review any use of oral glucocorticoids or antibiotics for exacerbations. We use validated symptom questionnaires such as the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fsinonasaltest.wustl.edu%2F&amp;token=ucDrxnLuYNidf73NHuLMBRTVpp4sxVxKfd7KHWEY5Ccf0So3OUW7xDw%2BNOGjp6mn&amp;TOPIC_ID=121194" target="_blank">Sino-Nasal Outcomes Test (SNOT-22)</a> to assess symptom severity of CRS-related QoL.</p><p class="headingAnchor" id="H1163583362"><span class="h1">REFRACTORY SYMPTOMS</span></p><p class="headingAnchor" id="H4069435771"><span class="h2">Reasons for inadequate response</span><span class="headingEndMark"> — </span>If a patient has not had improvement in their symptoms and quality of life (QoL) after using <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> and an intranasal corticosteroid (INCS) for at least two months, we confirm that the patient used these therapies consistently during the treatment period and with proper technique.</p><p>If there was good adherence and technique, we reconsider the diagnosis by considering the following questions:</p><p class="bulletIndent1"><span class="glyph">●</span>Was there convincing objective evidence on endoscopic exam or imaging to support a diagnosis of CRSsNP? (See  <a class="medical medical_review" href="/z/d/html/7528.html" rel="external">"Chronic rhinosinusitis: Clinical manifestations, pathophysiology, and diagnosis", section on 'Demonstration of mucosal disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Is CRSsNP the correct subtype? (See  <a class="medical medical_review" href="/z/d/html/7528.html" rel="external">"Chronic rhinosinusitis: Clinical manifestations, pathophysiology, and diagnosis", section on 'Determining the subtype of disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Is odontogenic sinusitis a possibility [<a href="#rid25">25</a>]? In one review, it was estimated that nearly 30 percent of unilateral maxillary sinusitis cases may arise from underlying dental pathology [<a href="#rid26">26</a>]. A complicated dental history or concerning examination can further increase clinical suspicion. Imaging of the teeth and collaboration with dental/oral surgeons are indicated. (See  <a class="medical medical_review" href="/z/d/html/3417.html" rel="external">"Epidemiology, pathogenesis, and clinical manifestations of odontogenic infections"</a> and  <a class="medical medical_review" href="/z/d/html/3416.html" rel="external">"Complications, diagnosis, and treatment of odontogenic infections"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Could some of the symptoms be attributable to conditions other than CRSsNP? Common mimics include various forms of rhinitis (without sinusitis), headache and facial pain syndromes, and laryngopharyngeal reflux. (See  <a class="medical medical_review" href="/z/d/html/7533.html" rel="external">"An overview of rhinitis"</a> and  <a class="medical medical_review" href="/z/d/html/3349.html" rel="external">"Evaluation of headache in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7528.html" rel="external">"Chronic rhinosinusitis: Clinical manifestations, pathophysiology, and diagnosis", section on 'Differential diagnosis'</a>.)</p><p></p><p>If an otolaryngologist has not been consulted yet, it is helpful to pursue referral at this point. (See <a class="local">'Referral'</a> above.)</p><p class="headingAnchor" id="H2062664720"><span class="h2">Choice of next intervention</span><span class="headingEndMark"> — </span>Even with optimal use of INCS and intranasal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>, many patients experience only modest improvement. There are several options for next steps, with few comparative studies to support one therapy over another. The following is the authors' approach  (<a class="graphic graphic_algorithm graphicRef141673" href="/z/d/graphic/141673.html" rel="external">algorithm 1</a>). Two common next steps are either short courses of oral glucocorticoids and/or antibiotics or referral to an otolaryngologist for sinus surgery.</p><p class="headingAnchor" id="H2095040945"><span class="h3">Short course of oral glucocorticoids and/or antibiotics</span><span class="headingEndMark"> — </span>For most patients with inadequate relief after several months of <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> and INCS, we favor the combination of an oral glucocorticoid and oral antibiotics for 10 to 14 days. This is common practice, although supporting data are sparse. The International Consensus on Allergy and Rhinology-Rhinosinusitis (ICAR-RS) lists both oral glucocorticoids and antibiotics as treatment options but does not specifically recommend either or the combination for patients with CRSsNP, due to lack of data [<a href="#rid2">2</a>]. If clearly purulent discharge is visible, we may prescribe an antibiotic alone, without oral glucocorticoids. However, it can be difficult even to appreciate if the mucus is purulent. Some patients with CRSsNP will have clearly mucopurulent drainage on exam, but most have only thickened secretions that are not clearly purulent, making the differentiation between infection and inflammation difficult without culture information. If there is no purulence but notable mucosal edema, we may prescribe glucocorticoids alone. If both purulent secretions and mucosal edema are present, we usually give combined therapy.</p><p class="bulletIndent1"><span class="glyph">●</span>In adults, the authors prefer <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 40 mg per day for five days, then 20 mg per day for five days, taken with food in the morning. However, the optimal regimen has not been determined, and other shorter or longer systemic glucocorticoid courses, depending on patient preference and comorbidities, are suitable. For example, longer courses of an oral glucocorticoid, such as 20 days, have also been suggested [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We select an antibiotic based on culture of material obtained endoscopically from a sinus cavity whenever possible. (Note that cultures obtained by swabbing the nasal cavities generally reflect skin flora and are not useful.) If culture is not possible, then the choice of antibiotics is empiric and guided by additional factors such as local resistance patterns and potential for adverse effects. Empiric choices of antibiotics for CRS are reviewed in more detail elsewhere (see  <a class="medical medical_review" href="/z/d/html/3412.html" rel="external">"Microbiology and antibiotic management of chronic rhinosinusitis", section on 'Empiric regimen selection'</a>). We usually give a 10- to 14-day course, occasionally extending it if the patient is not fully improved or purulence persists at the end of 14 days.</p><p></p><p class="headingAnchor" id="H3316048670"><span class="h4">Efficacy</span><span class="headingEndMark"> — </span>High-quality evidence is lacking for oral glucocorticoids, oral antibiotics, or the combination specifically for CRSsNP [<a href="#rid2">2</a>]. In one retrospective study, 100 patients with CRSsNP were treated either with oral (nonmacrolide) antibiotics, oral glucocorticoids (variable regimens), or both for 10 to 21 days [<a href="#rid27">27</a>]. All three groups showed similar improvement in objective Lung-MacKay scores, and there was no difference in the percentage of each group that eventually required surgery. Use of glucocorticoids is also based on studies showing that approximately 55 percent of CRSsNP have type 2 inflammation, which could reasonably be expected to improve with oral glucocorticoids [<a href="#rid2">2</a>]. Note that the repeated use of systemic glucocorticoids and antibiotics, even if helpful over the short term, is not an effective long-term management plan due to the long-term adverse effects  (<a class="graphic graphic_table graphicRef65998" href="/z/d/graphic/65998.html" rel="external">table 3</a>).</p><p class="headingAnchor" id="H4173650073"><span class="h3">Functional endoscopic sinus surgery</span><span class="headingEndMark"> — </span>In patients in whom medical treatment does not result in sufficient improvement in symptoms, the next logical step is sinus surgery. Functional endoscopic sinus surgery (FESS) involves removing tissue around the natural drainage pathways (the ostia) of the paranasal sinuses to widen the outflow tracts. Restoring physiologic sinus ventilation and drainage can facilitate the gradual resolution of mucosal disease. The mucosal lining is disturbed as minimally as possible. CRSsNP can involve some or all of the four sinuses (frontal, ethmoid, maxillary, and sphenoid), and sinus surgery can similarly involve just some or all of the sinuses at the discretion of the surgeon  (<a class="graphic graphic_figure graphicRef141534" href="/z/d/graphic/141534.html" rel="external">figure 2</a>).</p><p>FESS typically requires general anesthesia and is most often performed through an endoscope, such that there is no external visible incisions. Patients will experience some discomfort and congestion for several days after the surgery. The major risk is bleeding, but absolute complication rates are low (eg, &lt;5 percent for all complications and &lt;1 percent for serious complications) [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H2627332024"><span class="h4">Indications for sinus surgery</span><span class="headingEndMark"> — </span>FESS does not directly treat the underlying inflammation that causes CRSsNP, and thus sinus surgery is not typically considered the first intervention for CRSsNP. Instead, FESS is performed in conjunction with medical management to control inflammatory processes. Without ongoing medical management, symptoms will usually return.</p><p>Indications for surgical intervention in patients with CRSsNP include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Failure of medical treatments (ie, those discussed above)</p><p class="bulletIndent1"><span class="glyph">●</span>Inability of topical therapies to penetrate the nasal passages despite medical therapy</p><p class="bulletIndent1"><span class="glyph">●</span>Bony erosion or extension of disease beyond the sinus cavities</p><p></p><p>CRS is an inflammatory disorder of the sinonasal mucosa, and underlying structural abnormalities, such as septal deviation and enlarged sinus structures (eg, turbinates, concha bullosa, large Haller cells), are not known to occur at a higher frequency in patients with CRS compared with controls [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H1320620802"><span class="h4">Approaches for severe or recurrent sinus disease</span><span class="headingEndMark"> — </span>In some cases of severe and/or recurrent inflammation despite maximal medical management and previous surgery, extended approaches are used. The most common is maximal widening of the openings of the sinuses. Examples include maxillary sinus mega-antrostomies to extend the opening to the floor of the nasal cavity and frontal sinus drill-out procedures (Modified Lothrop or Draf III) that remove the entire floor of the frontal sinus while connecting the right and left sinuses together. These procedures are beyond the scope of this topic but are employed in cases of severe CRSsNP.</p><p class="headingAnchor" id="H437639006"><span class="h4">Efficacy</span><span class="headingEndMark"> — </span>In a 2017 systematic review and meta-analysis, FESS was compared with continued medical treatment in patients who had already received appropriate medical therapy, defined in this analysis as usually consisting of eight weeks of INCS and three weeks of antibiotics. Approximately one-half of the studies also included one to two weeks of oral glucocorticoids [<a href="#rid28">28</a>]. Patients chose their treatment using shared decision making. Over the subsequent year, patients who underwent surgery attained relatively greater improvement compared with those who continued medical therapy. However, it was not possible to make a direct comparison because patients with lower QoL scores tended to choose FESS, while those with higher scores chose continued medical management.</p><p>Several studies have shown durable improvement in patient symptoms with surgery over 5 and 10 years [<a href="#rid29">29,30</a>]. In addition, in patients with both asthma and CRS, there is some evidence that FESS combined with ongoing medical therapy results in better long-term asthma control than medical management alone [<a href="#rid31">31,32</a>]. A systematic review and meta-analysis of 22 studies examining the impact of FESS on asthma in patients with CRS demonstrated reduction in asthma exacerbations, decrease in systemic and inhaled corticosteroids, and overall improvement in asthma control; however, there was no improvement in lung function [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H2030678797"><span class="h4">Adjuncts to sinus surgery</span><span class="headingEndMark"> — </span>Adjuncts to sinus surgery include steroid-eluting stents and dressings.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Steroid-eluting stents and dressings</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Implants</strong> – Bioabsorbable sinus implants that elute <a class="drug drug_general" data-topicid="9663" href="/z/d/drug information/9663.html" rel="external">mometasone</a> are approved by the US Food and Drug Administration (FDA) specifically for maintaining the patency of the frontal or ethmoid sinus openings after FESS [<a href="#rid34">34,35</a>]. The implants deliver 370 mcg of mometasone furoate over 30 days. Data from two randomized trials including 143 patients demonstrated that the drug-eluting ethmoid implants reduced the need for postoperative interventions and oral glucocorticoids [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nasal packing materials</strong> – At the end of surgery, surgeons can mix glucocorticoid with bioabsorbable packing material. Although this technique is presumably safer than repeated or sustained oral glucocorticoids, the safety of direct application and systemic uptake of this non-US FDA-approved method is not definitively known, and supporting evidence is limited [<a href="#rid37">37,38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Balloon ostial dilation</strong> — Balloon ostial dilation (BOD) is a procedure in which the frontal, sphenoid, or maxillary sinus ostium is dilated using a balloon catheter. This procedure also goes by other names, including "sinus ostial dilation" and "balloon catheter sinusotomy," but "balloon ostial dilation" is the terminology recommended by the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS). Note that BOD cannot be used to widen the ethmoid sinuses given the multiple air cells involved and convoluted drainage pathway. The ethmoid sinuses are typically an area of significant inflammation in CRS, and FESS is still needed when the ethmoid sinuses are involved.</p><p></p><p class="bulletIndent1">BOD does not involve surgical removal of tissue and can be performed in the office setting under local anesthesia in adolescent and adults. Because no tissue is removed, BOD is less effective compared with FESS in patients with significant inflammation, and there is concern that allowing diseased tissue to remain in place inhibits resolution of the inflammation. However, it may be an adequate alternative to FESS in those with mild disease. Uptake of this technique is variable. Often, it is performed in the same setting as traditional FESS as an adjunct technique to facilitate widening of the drainage pathway of more difficult sinuses (ie, frontal). Although durable improvement in CRS symptoms have been demonstrated with this technique, data comparing BOD and FESS for the management of CRS are limited and mostly sponsored by manufacturers of the balloon catheters [<a href="#rid39">39-44</a>].</p><p></p><p class="bulletIndent1">A 2018 consensus statement suggested that BOD may be beneficial as an adjunct procedure to FESS in patients with CRSsNP and in widening stenosed sinus openings in patients with previous sinus surgery [<a href="#rid45">45</a>].</p><p></p><p class="headingAnchor" id="H2286766068"><span class="h4">Need for revision sinus surgery</span><span class="headingEndMark"> — </span>In most studies evaluating long-term outcomes (eg, 5 to 10 years) after FESS, between 15 and 20 percent of patients with all types of CRS require repeat surgery, although most of these patients have CRSwNP. In one study that included data specifically on outcomes in patients with CRSsNP, only 3 percent of 59 patients required repeat surgery over the course of a decade of follow-up [<a href="#rid30">30</a>].</p><p>Common reasons for patients to not improve after FESS or to require repeat sinus surgery include:</p><p class="bulletIndent1"><span class="glyph">●</span>Inconsistent adherence to maintenance therapies (usually intranasal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> and INCS).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Incomplete or improper sinus surgery. One possible complication of FESS is mucus recirculation syndrome, a condition in which mucus draining through a sinus ostium reenters the sinus through a different ostium rather than draining down the nasopharynx [<a href="#rid46">46-52</a>]. The vast majority of cases involve the maxillary sinus [<a href="#rid46">46</a>]. In most cases, the problematic ostium was surgically created, although mucus recirculation can also arise from an accessory sinus ostia (which can be congenital or form spontaneously). Patients suspected of having this disorder should be evaluated by an otolaryngology specialist [<a href="#rid48">48</a>]. Irrigation may sometimes resolve this problem. However, surgery to remove the tissue separating the two ostia and create a single ostium has been reported to be curative [<a href="#rid46">46,53</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Unrecognized and untreated comorbid conditions, such as allergic rhinitis or immunodeficiency.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An unrecognized odontogenic source of infection [<a href="#rid25">25</a>]. (See <a class="local">'Reasons for inadequate response'</a> above.)</p><p></p><p class="headingAnchor" id="H3010313828"><span class="h1">OTHER MEDICAL THERAPIES</span></p><p class="headingAnchor" id="H88288588"><span class="h2">Extended course of a macrolide antibiotic</span><span class="headingEndMark"> — </span>In patients with CRSsNP, macrolides are used primarily for their antiinflammatory and immunomodulatory effects, rather than their antimicrobial effects, similar to their use in asthma [<a href="#rid54">54</a>]. Administration of an oral macrolide antibiotic for 4 to 12 weeks is a treatment option for CRSsNP that has not responded to other measures [<a href="#rid2">2</a>]. This approach is sometimes chosen for patients with non-type 2, noneosinophilic inflammation, although there are no definite biomarkers to identify patients who will respond. (See <a class="local">'The role of endotypes'</a> below.)</p><p>If we select this option as a result of shared decision making with the patient, we usually administer a 12-week course of <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> (either 250 or 500 mg three times per week) after reviewing the small risk of adverse effects and assessing for possible drug interactions. However, the best macrolide antibiotic to choose, the dose of drug, and the duration of treatment have not been studied adequately. We favor azithromycin because it is generally well tolerated and has fewer drug interactions and adverse effects than other macrolides. We avoid <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a> in particular in patients with cardiovascular disease. (See  <a class="medical medical_review" href="/z/d/html/474.html" rel="external">"Azithromycin and clarithromycin", section on 'Adverse reactions'</a>.)</p><p>Evidence of the benefit of macrolides in CRS is limited, and the available studies do not clearly show that macrolides are superior to other treatments.</p><p class="bulletIndent1"><span class="glyph">●</span>In a 2017 systematic review that included patients with all types of CRS, the quality of the evidence for use of macrolides in CRS was low in general but looked most promising for patients with NP who had already undergone surgery [<a href="#rid55">55</a>]. Only three trials included in the systematic review were limited to patients with CRSsNP. In one, 12 weeks of a daily macrolide provided some benefit over placebo; however, the benefit was not sustained after cessation of therapy [<a href="#rid56">56</a>]. In the other two studies, macrolides were compared with other treatments (<a class="drug drug_general" data-topicid="9663" href="/z/d/drug information/9663.html" rel="external">mometasone</a> nasal spray or Chinese herbal medicine) without placebo controls and appeared to have similar efficacy [<a href="#rid57">57,58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A subsequent randomized trial compared four weeks of <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a> plus a short course of oral glucocorticoid (ie, the approach mentioned previously) with eight weeks of <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a> in 57 patients with CRSsNP [<a href="#rid59">59</a>]. Thirty-seven patients completed the study, and Sino-Nasal Outcome Test (SNOT-20) and imaging scores improved to similar degrees, although the group receiving amoxicillin-clavulanate had significantly more adverse reactions. After treatment, functional endoscopic sinus surgery (FESS) was required for uncontrolled symptoms in 35 and 41 percent of patients who received amoxicillin-clavulanate plus glucocorticoids or clarithromycin, respectively.</p><p></p><p>In an effort to clarify the role of long-term macrolides, the Defining best Management for Adults with Chronic RhinOsinusitis (MACRO) trial, a multicenter, randomized clinical trial designed to compare long-term macrolide therapy with endoscopic sinus surgery in patients in whom initial therapy with <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> and INCS failed, has been initiated in the United Kingdom [<a href="#rid60">60-62</a>]. Results are pending.</p><p class="headingAnchor" id="H1185783294"><span class="h2">Biologics for patients with coexistent conditions</span><span class="headingEndMark"> — </span>No biologic agent is specifically approved for the treatment of CRSsNP, and data demonstrating efficacy for CRSsNP are very preliminary [<a href="#rid63">63,64</a>]. However, biologic therapies can be given to patients with concomitant conditions for which there are established biologic treatments, most commonly asthma. In patients with both CRSsNP and moderate-to-severe asthma that is not adequately controlled with inhaled glucocorticoids and long-acting beta agonists, we sometimes offer one of the biologics for asthma: <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">dupilumab</a>, <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a>, <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">mepolizumab</a>, <a class="drug drug_general" data-topicid="107564" href="/z/d/drug information/107564.html" rel="external">reslizumab</a>, <a class="drug drug_general" data-topicid="115768" href="/z/d/drug information/115768.html" rel="external">benralizumab</a>, or <a class="drug drug_general" data-topicid="134676" href="/z/d/drug information/134676.html" rel="external">tezepelumab</a>, with the choice based on the characteristics of the patient's asthma  (<a class="graphic graphic_table graphicRef118483" href="/z/d/graphic/118483.html" rel="external">table 4</a>) (see  <a class="medical medical_review" href="/z/d/html/551.html" rel="external">"Treatment of severe asthma in adolescents and adults"</a>). The same approach can apply to patients with other coexisting conditions that are treated with biologics (eg, severe atopic dermatitis, urticaria refractory to antihistamines, etc).</p><p class="headingAnchor" id="H575406156"><span class="h3">The role of endotypes</span><span class="headingEndMark"> — </span>Endotypes refer to classifications of CRS based on pathophysiology and profiles of underlying inflammation, as determined by biomarkers and gene expression [<a href="#rid65">65</a>]. In patients with asthma, endotyping may help direct therapy as patients with type 2 inflammation may respond better to glucocorticoids and certain biologic therapies (ie, <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">dupilumab</a> and <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a>). CRSsNP can be categorized into three different endotypes, independent of the presence of polyps: type 1 (21 percent), type 2 (55 percent), and type 3 (27 percent), at least in European and North American patient populations [<a href="#rid2">2,66,67</a>]. However, the prevalence of the various endotypes differs around the world, and some patients do not appear to have any of these endotypes [<a href="#rid68">68</a>].</p><p>The subset of patients with both CRSsNP and asthma with evidence of type 2 inflammation could be expected to respond to some degree to biologics that target immunoglobulin E (IgE; <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a>) or interleukin (IL) 4/13 (<a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">dupilumab</a>). Patients with prominent eosinophilia in the peripheral blood or respiratory tract tissues could be expected to respond to biologics that target IL-5 (<a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">mepolizumab</a> and <a class="drug drug_general" data-topicid="107564" href="/z/d/drug information/107564.html" rel="external">reslizumab</a>) or its receptor (<a class="drug drug_general" data-topicid="115768" href="/z/d/drug information/115768.html" rel="external">benralizumab</a>).</p><p>Although the definition of type 2 inflammation is not standardized, the following criteria are used most often to identify the presence of type 2 inflammation:</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated blood eosinophils (&gt;150/microL)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Elevated total IgE &gt;100 international units/mL</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sensitivity to environmental allergens on skin testing or in vitro allergen-specific IgE immunoassays</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sinus tissue eosinophilia (when this information is available as a result of sinus surgery)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fractional exhaled nitric oxide (FeNO) ≥25 ppb (in patients with concomitant asthma)</p><p></p><p>Although there is some preliminary evidence of benefit of biologics in CRSsNP [<a href="#rid63">63,64</a>], more study is needed.</p><p class="headingAnchor" id="H4151461140"><span class="h2">Other therapies without strong supporting evidence</span><span class="headingEndMark"> — </span>Additional therapies that lack adequate supporting evidence include traditional Chinese medicines [<a href="#rid69">69</a>], topical or systemic antifungals [<a href="#rid70">70</a>], probiotics [<a href="#rid71">71</a>], acupuncture [<a href="#rid72">72</a>], Ayurvedic medicine [<a href="#rid73">73</a>], crenotherapy [<a href="#rid74">74</a>], Manuka Honey, mucoactive drugs, decongestants, herbal treatments, and homeopathy. In agreement with guidelines, we do not advocate use of these therapies [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H3253060667"><span class="h1">MAINTENANCE THERAPY</span><span class="headingEndMark"> — </span>For patients whose symptoms become adequately controlled as a result of medical or surgical treatment, maintenance with <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> (rinse or spray) and intranasal corticosteroids (INCS) is usually continued long term. If symptoms are completely controlled, we gradually lower therapy, first reducing the INCS dosing (including conversion of a rinse or exhalation delivery system to a spray) over months to years. A trial off INCS could be considered after being stable for several months or longer on the lowest dose. Saline spray or rinse is sometimes maintained indefinitely, although some patients may be able to successfully stop them as well.</p><p class="headingAnchor" id="H1042100373"><span class="h1">TREATING EXACERBATIONS</span><span class="headingEndMark"> — </span>Acute exacerbations of CRS have been defined as transient worsening of symptoms that returns to baseline either without intervention or after intervention with antibiotics and/or glucocorticoids [<a href="#rid2">2</a>]. The cause of acute exacerbations is likely multifactorial and includes viral infections (likely the most frequent cause), bacterial infections, medication nonadherence, and allergen or irritant exposure. The evidence for treatment of CRSsNP exacerbations is extremely limited.</p><p>Ideally, patients with CRSsNP who experience worsening symptoms should be evaluated with nasal endoscopy because the information obtained may be able to clarify whether a bacterial infection is likely or not. When a bacterial infection is suspected (symptoms lasting more than seven days with purulent nasal drainage), we suggest an endoscopically obtained sinus culture to guide antibiotic therapy. Debridement of purulent secretions may also be helpful. The addition of an oral glucocorticoid can be considered when severe edema is present on examination, when patients have had previous favorable responses to glucocorticoids, or for a coexisting asthma exacerbation.</p><p class="bulletIndent1"><span class="glyph">●</span>Oral antibiotics are often given to treat exacerbations of CRS with purulent secretions. Patients with CRSsNP with uncomplicated bacterial infections can be treated similarly to an acute uncomplicated bacterial sinusitis  (<a class="graphic graphic_algorithm graphicRef106156" href="/z/d/graphic/106156.html" rel="external">algorithm 2</a>). (See  <a class="medical medical_review" href="/z/d/html/83012.html" rel="external">"Uncomplicated acute sinusitis and rhinosinusitis in adults: Treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A brief escalation of topical corticosteroid therapy can be sufficient to alleviate symptoms of an acute exacerbation in some patients. Examples include changing from a corticosteroid nasal spray to undiluted <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">budesonide</a> respules or to a 10- to 14-day tapering course of oral glucocorticoids (see <a class="local">'Intranasal corticosteroids'</a> above). Following resolution of the acute exacerbation, the patient should return to their usual intranasal corticosteroid (INCS) delivery mode to minimize potential adverse effects of the concentrated budesonide. Oral glucocorticoids are sometimes indicated for concomitant asthma exacerbations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Irrigations with antibiotic solutions are also used both for exacerbations and as an adjunctive therapy, typically in patients who have undergone previous sinus surgery but continue to produce mucopurulent secretions [<a href="#rid75">75</a>]. If we offer this treatment, we base the choice of antibiotic on culture data and typically treat for two to four weeks, performing a follow-up examination near the conclusion of treatment. Studies of efficacy in all types of CRS are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/3412.html" rel="external">"Microbiology and antibiotic management of chronic rhinosinusitis", section on 'Limited role for other antibiotic routes'</a>.)</p><p></p><p class="headingAnchor" id="H2310970174"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H3243280842"><span class="h2">Children</span><span class="headingEndMark"> — </span>Medical management of CRSsNP in children includes the use of <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> and intranasal corticosteroids (INCS) as in adults [<a href="#rid2">2</a>]. Children vary in the age at which they can perform irrigations themselves. Monitoring growth and other signs of systemic glucocorticoid adverse effects, especially in children who have other topical corticosteroid exposure (eg, skin, lungs, gastrointestinal tract), helps with management choices. For acute exacerbations, we use treatment algorithms developed for acute bacterial rhinosinusitis  (<a class="graphic graphic_algorithm graphicRef135260" href="/z/d/graphic/135260.html" rel="external">algorithm 3</a> and <a class="graphic graphic_algorithm graphicRef135256" href="/z/d/graphic/135256.html" rel="external">algorithm 4</a>) (see  <a class="medical medical_review" href="/z/d/html/5999.html" rel="external">"Acute bacterial rhinosinusitis in children: Microbiology and management"</a>). Systemic antibiotics with or without systemic glucocorticoids can be considered [<a href="#rid76">76</a>].</p><p>Important differences in the management of CRSsNP in children and adults are the following [<a href="#rid77">77</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The role of adenoidal hypertrophy is more important in children, and, in children with enlarged adenoids, adenoidectomy should be performed before functional endoscopic sinus surgery (FESS) is considered.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The use of long-term antibiotics (macrolides or other) has not been shown to be effective.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The impact of biologics on pediatric CRSsNP has not been studied.</p><p></p><p class="headingAnchor" id="H2952347798"><span class="h3">Surgical interventions in children</span><span class="headingEndMark"> — </span>Surgical procedures should be considered in children only after medical therapy has failed, and decisions should be individualized.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adenoidectomy </strong>– In children with CRS and adenoidal hypertrophy who have not improved sufficiently with medical therapy, adenoidectomy appears beneficial in observational studies, although controlled trials are lacking [<a href="#rid78">78,79</a>]. Adenoidectomy is suggested before FESS in young children with CRS and adenoidal hypertrophy [<a href="#rid78">78,80</a>]. The available literature regarding adenoidectomy in children with CRS is reviewed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/6296.html" rel="external">"Tonsillectomy and/or adenoidectomy in children: Indications and contraindications", section on 'Chronic sinusitis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Functional endoscopic sinus surgery </strong>– FESS in children appears to be safe, but efficacy compared with other surgical interventions, biologics, or ongoing medical therapies is unclear. FESS in children is usually performed only on the maxillary sinuses, which are lavaged during the same procedure. A 2013 systematic review of the literature evaluating FESS for the treatment of refractory CRS in children included 11 studies [<a href="#rid81">81</a>]. Among those, there were three prospective studies but no randomized, controlled trials and no uniformity in outcomes assessed. There were 6 complications in 440 surgeries (1.4 percent). Most studies reported subjective measures of improvement with success rates between 82 and 100 percent, but the quality of the evidence was low.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pediatric balloon ostial dilation</strong> — Balloon ostial dilation (BOD) is an option for children with CRSsNP, which can be performed at the discretion of the otolaryngologist, but its role in the management of CRSsNP requires further study. It may be difficult for children to tolerate as an office procedure. Most studies have involved widening the drainage pathways of the maxillary sinuses only. Earlier prospective pediatric cohort studies of BOD, with or without ethmoidectomy or adenoidectomy, suggested benefit beyond that of adenoidectomy alone [<a href="#rid82">82-84</a>]. A 2020 meta-analysis of BOD in children with CRS identified 10 studies, of which three compared BOD with adenoidectomy, <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> irrigation, or maxillary antrostomy (ie, surgical widening of drainage pathways) [<a href="#rid85">85</a>]. Two of these studies found BOD to be inferior to standard techniques. In a subsequent study, BOD appeared similarly effective to adenoidectomy plus lavage of the maxillary sinuses [<a href="#rid86">86</a>].</p><p></p><p class="headingAnchor" id="H3843258260"><span class="h2">Pregnancy</span><span class="headingEndMark"> — </span>INCS sprays used at the lowest effective dose and <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> irrigations are considered safe during pregnancy [<a href="#rid87">87</a>]. High-quality evidence for management options for CRSsNP specifically during pregnancy is lacking. Studies of the use of INCS in pregnancy for other allergic disorders are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5552.html" rel="external">"Recognition and management of allergic disease during pregnancy"</a>.)</p><p>For acute exacerbations during pregnancy, decisions on management should account for pregnancy safety data for antibiotics and oral glucocorticoids.</p><p class="headingAnchor" id="H2126272694"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Long-term outcomes in patients with CRSsNP are poorly studied. An international registry has been established to collect data on the natural history of the disorder and treatment outcomes [<a href="#rid88">88</a>].</p><p class="headingAnchor" id="H79192746"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110441.html" rel="external">"Society guideline links: Chronic rhinosinusitis"</a>.)</p><p class="headingAnchor" id="H1548879396"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/86637.html" rel="external">"Patient education: Chronic sinusitis (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/86630.html" rel="external">"Patient education: How to rinse out your nose with salt water (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/378.html" rel="external">"Patient education: Chronic rhinosinusitis (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H3967671164"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions </strong>– Chronic rhinosinusitis without nasal polyposis (CRSsNP) is a complex inflammatory condition involving the paranasal sinuses and linings of the nasal passages, which lasts 12 weeks or longer. Symptoms include nasal obstruction or blockage, thick nasal drainage, facial pressure, and reduction in sense of smell. Nasal polyps are not present in CRSsNP. (See  <a class="medical medical_review" href="/z/d/html/7528.html" rel="external">"Chronic rhinosinusitis: Clinical manifestations, pathophysiology, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial therapies </strong>– Our treatment approach is depicted in the algorithm and is consistent with multiple guidelines  (<a class="graphic graphic_algorithm graphicRef141673" href="/z/d/graphic/141673.html" rel="external">algorithm 1</a>). In patients with CRSsNP, we suggest a combination of intranasal corticosteroids (INCS) and intranasal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> as initial therapy, rather than either therapy alone or treatment with oral glucocorticoids or antibiotics (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Treatment should be continued for at least two months as improvement may be gradual. It is important to teach patients the proper techniques for using nasal sprays and nasal irrigations  (<a class="graphic graphic_figure graphicRef141563" href="/z/d/graphic/141563.html" rel="external">figure 1</a>). (See <a class="local">'Initial interventions for all patients'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Intranasal corticosteroids </strong>– We begin with commercially available nasal sprays  (<a class="graphic graphic_table graphicRef55833" href="/z/d/graphic/55833.html" rel="external">table 2</a>). If patients have insufficient benefit from nasal sprays, we try other delivery systems, such as adding corticosteroid solutions to <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> irrigation, nasal drops, nasal nebulizations, or exhalation delivery systems. (See <a class="local">'Intranasal corticosteroids'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Intranasal </strong><strong>saline</strong> – We suggest high-volume (60 to 240 mL) <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> irrigations rather than low-volume saline sprays (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Isotonic saline is better tolerated than hypertonic saline. (See <a class="local">'Saline'</a> above.)</p><p></p><p class="bulletIndent1">Even with optimal and consistent use, many patients experience only modest improvement with these initial interventions. (See <a class="local">'Reasons for inadequate response'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with persistent symptoms </strong>– For patients with persistent symptoms, there are several options for additional treatments but very few studies to define their relative efficacy. We suggest a short course of both oral glucocorticoids and antibiotics (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>); however, treating with either glucocorticoids or antibiotics as monotherapy or referral for sinus surgery are reasonable alternatives in these patients  (<a class="graphic graphic_algorithm graphicRef141673" href="/z/d/graphic/141673.html" rel="external">algorithm 1</a>). (See <a class="local">'Choice of next intervention'</a> above and <a class="local">'Short course of oral glucocorticoids and/or antibiotics'</a> above and <a class="local">'Referral'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sinus surgery </strong>– For patients with persistent symptoms despite the nonsurgical interventions mentioned above, we suggest sinus surgery (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Functional endoscopic sinus surgery (FESS) involves removing tissue around the natural drainage pathways (the ostia) of the paranasal sinuses to widen the outflow tracts  (<a class="graphic graphic_figure graphicRef141534" href="/z/d/graphic/141534.html" rel="external">figure 2</a>). Restoring physiologic sinus ventilation and drainage can facilitate the gradual resolution of mucosal disease, but surgery must be followed by ongoing medical therapy to address mucosal inflammation. (See <a class="local">'Functional endoscopic sinus surgery'</a> above.)</p><p></p><p class="bulletIndent1">The surgical approach differs in children. Many children with CRSsNP will have enlarged adenoids, and, in such patients, adenoidectomy should be performed before FESS is considered. (See <a class="local">'Children'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other medical therapies </strong>– Other medical therapies include an extended course of macrolide antibiotics and one of several respiratory biologic therapies if there is an indication for a biologic (usually moderate-to-severe asthma). These treatments can be prescribed in patients who have contraindications to sinus surgery or have recurrent symptoms following surgery. (See <a class="local">'Other medical therapies'</a> above.)</p><p></p><p class="bulletIndent1">There are no approved biologic therapies for CRSsNP, but if the patient has a coexisting condition that can be treated with a respiratory biologic (ie, <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">dupilumab</a>, <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a>, <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">mepolizumab</a>, <a class="drug drug_general" data-topicid="107564" href="/z/d/drug information/107564.html" rel="external">reslizumab</a>, <a class="drug drug_general" data-topicid="115768" href="/z/d/drug information/115768.html" rel="external">benralizumab</a>, or <a class="drug drug_general" data-topicid="134676" href="/z/d/drug information/134676.html" rel="external">tezepelumab</a>), the CRSsNP symptoms may also improve. (See <a class="local">'Biologics for patients with coexistent conditions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maintenance therapy </strong>– For patients whose symptoms become adequately controlled as a result of medical or surgical treatment, maintenance with <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> (rinse or spray) and INCS is usually continued long term. We have the patient continue with the delivery method that worked best for them, at the lowest dose that maintains symptom control. (See <a class="local">'Maintenance therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Managing acute exacerbations </strong>– CRSsNP can worsen periodically due to viral or bacterial infections, medication nonadherence, and allergen or irritant exposure. Symptoms sometime spontaneously return to baseline, but, if not, the choice of treatment (oral or topical antibiotics, a temporary change to a more intense form of INCS, or a brief course of oral glucocorticoids) depends on the suspected cause. (See <a class="local">'Treating exacerbations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Long-term outcomes in patients with CRSsNP are poorly studied, although many patients require indefinite treatment. (See <a class="local">'Prognosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Hopkins C, Philpott C, Crowe S, et al. Identifying the most important outcomes for systematic reviews of interventions for rhinosinusitis in adults: working with Patients, Public and Practitioners. Rhinology 2016; 54:20.</a></li><li><a class="nounderline abstract_t">Orlandi RR, Kingdom TT, Smith TL, et al. International consensus statement on allergy and rhinology: rhinosinusitis 2021. Int Forum Allergy Rhinol 2021; 11:213.</a></li><li><a class="nounderline abstract_t">Fokkens WJ, Lund VJ, Hopkins C, et al. Executive summary of EPOS 2020 including integrated care pathways. Rhinology 2020; 58:82.</a></li><li><a class="nounderline abstract_t">Taccariello M, Parikh A, Darby Y, Scadding G. Nasal douching as a valuable adjunct in the management of chronic rhinosinusitis. Rhinology 1999; 37:29.</a></li><li><a class="nounderline abstract_t">Chang YS, Chen PL, Hung JH, et al. Orbital complications of paranasal sinusitis in Taiwan, 1988 through 2015: Acute ophthalmological manifestations, diagnosis, and management. PLoS One 2017; 12:e0184477.</a></li><li><a class="nounderline abstract_t">Szyfter W, Bartochowska A, Borucki Ł, et al. Simultaneous treatment of intracranial complications of paranasal sinusitis. Eur Arch Otorhinolaryngol 2018; 275:1165.</a></li><li><a class="nounderline abstract_t">Caranfa JT, Yoon MK. Septic cavernous sinus thrombosis: A review. Surv Ophthalmol 2021; 66:1021.</a></li><li><a class="nounderline abstract_t">Chitsuthipakorn W, Kanjanawasee D, Hoang MP, et al. Optimal Device and Regimen of Nasal Saline Treatment for Sinonasal Diseases: Systematic Review. OTO Open 2022; 6:2473974X221105277.</a></li><li><a class="nounderline abstract_t">Pynnonen MA, Mukerji SS, Kim HM, et al. Nasal saline for chronic sinonasal symptoms: a randomized controlled trial. Arch Otolaryngol Head Neck Surg 2007; 133:1115.</a></li><li><a class="nounderline abstract_t">Chong LY, Head K, Hopkins C, et al. Intranasal steroids versus placebo or no intervention for chronic rhinosinusitis. Cochrane Database Syst Rev 2016; 4:CD011996.</a></li><li><a class="nounderline abstract_t">Wormald PJ, Cain T, Oates L, et al. A comparative study of three methods of nasal irrigation. Laryngoscope 2004; 114:2224.</a></li><li><a class="nounderline abstract_t">Kanjanawasee D, Seresirikachorn K, Chitsuthipakorn W, Snidvongs K. Hypertonic Saline Versus Isotonic Saline Nasal Irrigation: Systematic Review and Meta-analysis. Am J Rhinol Allergy 2018; 32:269.</a></li><li><a class="nounderline abstract_t">Keen M, Foreman A, Wormald PJ. The clinical significance of nasal irrigation bottle contamination. Laryngoscope 2010; 120:2110.</a></li><li><a class="nounderline abstract_t">Chiu AG, Palmer JN, Woodworth BA, et al. Baby shampoo nasal irrigations for the symptomatic post-functional endoscopic sinus surgery patient. Am J Rhinol 2008; 22:34.</a></li><li><a class="nounderline abstract_t">Peters AT, Spector S, Hsu J, et al. Diagnosis and management of rhinosinusitis: a practice parameter update. Ann Allergy Asthma Immunol 2014; 113:347.</a></li><li><a class="nounderline abstract_t">Snidvongs K, Kalish L, Sacks R, et al. Sinus surgery and delivery method influence the effectiveness of topical corticosteroids for chronic rhinosinusitis: systematic review and meta-analysis. Am J Rhinol Allergy 2013; 27:221.</a></li><li><a class="nounderline abstract_t">Sindwani R, Han JK, Soteres DF, et al. NAVIGATE I: Randomized, Placebo-Controlled, Double-Blind Trial of the Exhalation Delivery System With Fluticasone for Chronic Rhinosinusitis With Nasal Polyps. Am J Rhinol Allergy 2019; 33:69.</a></li><li><a class="nounderline abstract_t">Leopold DA, Elkayam D, Messina JC, et al. NAVIGATE II: Randomized, double-blind trial of the exhalation delivery system with fluticasone for nasal polyposis. J Allergy Clin Immunol 2019; 143:126.</a></li><li><a class="nounderline abstract_t">Wang C, Lou H, Wang X, et al. Effect of budesonide transnasal nebulization in patients with eosinophilic chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol 2015; 135:922.</a></li><li><a class="nounderline abstract_t">Harvey RJ, Schlosser RJ. Local drug delivery. Otolaryngol Clin North Am 2009; 42:829.</a></li><li><a class="nounderline abstract_t">Bernstein JA, White AA, Han JK, et al. Review of evidence supporting the use of nasal corticosteroid irrigation for chronic rhinosinusitis. Ann Allergy Asthma Immunol 2023; 130:46.</a></li><li><a class="nounderline abstract_t">Snidvongs K, Kalish L, Sacks R, et al. Topical steroid for chronic rhinosinusitis without polyps. Cochrane Database Syst Rev 2011; :CD009274.</a></li><li><a class="nounderline abstract_t">Hutson K, Clark A, Hopkins C, et al. Evaluation of Smoking as a Modifying Factor in Chronic Rhinosinusitis. JAMA Otolaryngol Head Neck Surg 2021; 147:159.</a></li><li><a class="nounderline abstract_t">Lechien JR, Saussez S, Hopkins C. Association between laryngopharyngeal reflux, gastroesophageal reflux and recalcitrant chronic rhinosinusitis: A systematic review. Clin Otolaryngol 2023; 48:501.</a></li><li><a class="nounderline abstract_t">Psillas G, Papaioannou D, Petsali S, et al. Odontogenic maxillary sinusitis: A comprehensive review. J Dent Sci 2021; 16:474.</a></li><li><a class="nounderline abstract_t">Kim SM. Definition and management of odontogenic maxillary sinusitis. Maxillofac Plast Reconstr Surg 2019; 41:13.</a></li><li><a class="nounderline abstract_t">Liu YF, Richardson CM, Bernard SH, et al. Antibiotics, steroids, and combination therapy in chronic rhinosinusitis without nasal polyps in adults. Ear Nose Throat J 2018; 97:167.</a></li><li><a class="nounderline abstract_t">Patel ZM, Thamboo A, Rudmik L, et al. Surgical therapy vs continued medical therapy for medically refractory chronic rhinosinusitis: a systematic review and meta-analysis. Int Forum Allergy Rhinol 2017; 7:119.</a></li><li><a class="nounderline abstract_t">Simmonds JC, Paz-Lansberg M, Scangas G, Metson R. Endoscopic sinus surgery for chronic rhinosinusitis: 22-item Sino-Nasal Outcome Test 5-year results. Int Forum Allergy Rhinol 2022; 12:257.</a></li><li><a class="nounderline abstract_t">Smith TL, Schlosser RJ, Mace JC, et al. Long-term outcomes of endoscopic sinus surgery in the management of adult chronic rhinosinusitis. Int Forum Allergy Rhinol 2019; 9:831.</a></li><li><a class="nounderline abstract_t">Senior BA, Kennedy DW, Tanabodee J, et al. Long-term impact of functional endoscopic sinus surgery on asthma. Otolaryngol Head Neck Surg 1999; 121:66.</a></li><li><a class="nounderline abstract_t">Chen FH, Zuo KJ, Guo YB, et al. Long-term results of endoscopic sinus surgery-oriented treatment for chronic rhinosinusitis with asthma. Laryngoscope 2014; 124:24.</a></li><li><a class="nounderline abstract_t">Vashishta R, Soler ZM, Nguyen SA, Schlosser RJ. A systematic review and meta-analysis of asthma outcomes following endoscopic sinus surgery for chronic rhinosinusitis. Int Forum Allergy Rhinol 2013; 3:788.</a></li><li class="breakAll">US Department of Health and Human Services. Propel sinus implant premarket approval application letter. https://www.accessdata.fda.gov/cdrh_docs/pdf10/P100044A.pdf (Accessed on January 16, 2023).</li><li class="breakAll">US Department of Health and Human Services. Propel mini sinus implant premarket approval application letter. https://www.accessdata.fda.gov/cdrh_docs/pdf10/p100044s018a.pdf (Accessed on January 16, 2023).</li><li><a class="nounderline abstract_t">Han JK, Marple BF, Smith TL, et al. Effect of steroid-releasing sinus implants on postoperative medical and surgical interventions: an efficacy meta-analysis. Int Forum Allergy Rhinol 2012; 2:271.</a></li><li><a class="nounderline abstract_t">More Y, Willen S, Catalano P. Management of early nasal polyposis using a steroid-impregnated nasal dressing. Int Forum Allergy Rhinol 2011; 1:401.</a></li><li><a class="nounderline abstract_t">Hong SD, Kim JH, Dhong HJ, et al. Systemic effects and safety of triamcinolone-impregnated nasal packing after endoscopic sinus surgery: a randomized, double-blinded, placebo-controlled study. Am J Rhinol Allergy 2013; 27:407.</a></li><li><a class="nounderline abstract_t">Sinha P, Tharakan T, Payne S, Piccirillo JF. Balloon Sinus Dilation Versus Functional Endoscopic Sinus Surgery for Chronic Rhinosinusitis: Systematic Review and Meta-Analysis. Ann Otol Rhinol Laryngol 2023; 132:578.</a></li><li><a class="nounderline abstract_t">Ahmed J, Pal S, Hopkins C, Jayaraj S. Functional endoscopic balloon dilation of sinus ostia for chronic rhinosinusitis. Cochrane Database Syst Rev 2011; :CD008515.</a></li><li><a class="nounderline abstract_t">Stankiewicz J, Tami T, Truitt T, et al. Transantral, endoscopically guided balloon dilatation of the ostiomeatal complex for chronic rhinosinusitis under local anesthesia. Am J Rhinol Allergy 2009; 23:321.</a></li><li><a class="nounderline abstract_t">Weiss RL, Church CA, Kuhn FA, et al. Long-term outcome analysis of balloon catheter sinusotomy: two-year follow-up. Otolaryngol Head Neck Surg 2008; 139:S38.</a></li><li><a class="nounderline abstract_t">Cutler J, Bikhazi N, Light J, et al. Standalone balloon dilation versus sinus surgery for chronic rhinosinusitis: a prospective, multicenter, randomized, controlled trial. Am J Rhinol Allergy 2013; 27:416.</a></li><li><a class="nounderline abstract_t">Bikhazi N, Light J, Truitt T, et al. Standalone balloon dilation versus sinus surgery for chronic rhinosinusitis: a prospective, multicenter, randomized, controlled trial with 1-year follow-up. Am J Rhinol Allergy 2014; 28:323.</a></li><li><a class="nounderline abstract_t">Piccirillo JF, Payne SC, Rosenfeld RM, et al. Clinical Consensus Statement: Balloon Dilation of the Sinuses. Otolaryngol Head Neck Surg 2018; 158:203.</a></li><li><a class="nounderline abstract_t">Kane KJ. Recirculation of mucus as a cause of persistent sinusitis. Am J Rhinol 1997; 11:361.</a></li><li><a class="nounderline abstract_t">Richtsmeier WJ. Top 10 reasons for endoscopic maxillary sinus surgery failure. Laryngoscope 2001; 111:1952.</a></li><li><a class="nounderline abstract_t">Tichenor WS, Adinoff A, Smart B, Hamilos DL. Nasal and sinus endoscopy for medical management of resistant rhinosinusitis, including postsurgical patients. J Allergy Clin Immunol 2008; 121:917.</a></li><li><a class="nounderline abstract_t">Matthews BL, Burke AJ. Recirculation of mucus via accessory ostia causing chronic maxillary sinus disease. Otolaryngol Head Neck Surg 1997; 117:422.</a></li><li><a class="nounderline abstract_t">Yanagisawa E, Yanagisawa K. Endoscopic view of recirculation phenomenon of the maxillary sinus. Ear Nose Throat J 1997; 76:196.</a></li><li><a class="nounderline abstract_t">Yanagisawa E, Weaver EM. Endoscopic view of the recirculation phenomenon of sphenoid sinus drainage. Ear Nose Throat J 1996; 75:68.</a></li><li><a class="nounderline abstract_t">Gutman M, Houser S. Iatrogenic maxillary sinus recirculation and beyond. Ear Nose Throat J 2003; 82:61.</a></li><li><a class="nounderline abstract_t">Patel A, deShazo RD, Stringer S. Diagnostic criteria for a curable form of chronic rhinosinusitis: the mucous recirculation syndrome. Am J Med 2014; 127:586.</a></li><li><a class="nounderline abstract_t">Pollock J, Chalmers JD. The immunomodulatory effects of macrolide antibiotics in respiratory disease. Pulm Pharmacol Ther 2021; 71:102095.</a></li><li><a class="nounderline abstract_t">Lasso A, Masoudian P, Quinn JG, et al. Long-term low-dose macrolides for chronic rhinosinusitis in adults - a systematic review of the literature. Clin Otolaryngol 2017; 42:637.</a></li><li><a class="nounderline abstract_t">Wallwork B, Coman W, Mackay-Sim A, et al. A double-blind, randomized, placebo-controlled trial of macrolide in the treatment of chronic rhinosinusitis. Laryngoscope 2006; 116:189.</a></li><li><a class="nounderline abstract_t">Jiang RS, Wu SH, Tsai CC, et al. Efficacy of Chinese herbal medicine compared with a macrolide in the treatment of chronic rhinosinusitis without nasal polyps. Am J Rhinol Allergy 2012; 26:293.</a></li><li><a class="nounderline abstract_t">Zeng M, Long XB, Cui YH, Liu Z. Comparison of efficacy of mometasone furoate versus clarithromycin in the treatment of chronic rhinosinusitis without nasal polyps in Chinese adults. Am J Rhinol Allergy 2011; 25:e203.</a></li><li><a class="nounderline abstract_t">Lechien JR, Debie G, Mahillon V, et al. A 10-Year Follow-Up of a Randomized Prospective Study of 2 Treatments for Chronic Rhinosinusitis Without Nasal Polyps and Investigation of the Impact of Gastroeosophageal Reflux Disease in the Resistance to Treatment. Ear Nose Throat J 2021; 100:569S.</a></li><li><a class="nounderline abstract_t">Philpott C, le Conte S, Beard D, et al. Clarithromycin and endoscopic sinus surgery for adults with chronic rhinosinusitis with and without nasal polyps: study protocol for the MACRO randomised controlled trial. Trials 2019; 20:246.</a></li><li><a class="nounderline abstract_t">Ta NH, Hopkins C, Vennik J, Philpott C. Optimising trial outcomes and patient retention for the MACRO trial for chronic rhinosinusitis. Rhinology 2019; 57:358.</a></li><li><a class="nounderline abstract_t">Blackshaw H, Vennik J, Philpott C, et al. Expert panel process to optimise the design of a randomised controlled trial in chronic rhinosinusitis (the MACRO programme). Trials 2019; 20:230.</a></li><li><a class="nounderline abstract_t">Bajpai S, Marino MJ, Rank MA, et al. Benefits of biologic therapy administered for asthma on co-existent chronic rhinosinusitis: A real-world study. Int Forum Allergy Rhinol 2021; 11:1152.</a></li><li><a class="nounderline abstract_t">Patel GB, Kudlaty EA, Guo A, et al. Impact of type 2 targeting biologics on acute exacerbations of chronic rhinosinusitis. Allergy Asthma Proc 2021; 42:417.</a></li><li><a class="nounderline abstract_t">Akdis CA, Bachert C, Cingi C, et al. Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma &amp; Immunology. J Allergy Clin Immunol 2013; 131:1479.</a></li><li><a class="nounderline abstract_t">Tan BK, Klingler AI, Poposki JA, et al. Heterogeneous inflammatory patterns in chronic rhinosinusitis without nasal polyps in Chicago, Illinois. J Allergy Clin Immunol 2017; 139:699.</a></li><li><a class="nounderline abstract_t">Klingler AI, Stevens WW, Tan BK, et al. Mechanisms and biomarkers of inflammatory endotypes in chronic rhinosinusitis without nasal polyps. J Allergy Clin Immunol 2021; 147:1306.</a></li><li><a class="nounderline abstract_t">Kato A, Peters AT, Stevens WW, et al. Endotypes of chronic rhinosinusitis: Relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches. Allergy 2022; 77:812.</a></li><li><a class="nounderline abstract_t">Cui J, Lin W, May BH, et al. Chinese herbal therapy in the management of rhinosinusitis-A systematic review and meta-analysis. PLoS One 2022; 17:e0278492.</a></li><li><a class="nounderline abstract_t">Head K, Sharp S, Chong LY, et al. Topical and systemic antifungal therapy for chronic rhinosinusitis. Cochrane Database Syst Rev 2018; 9:CD012453.</a></li><li><a class="nounderline abstract_t">Bianco MR, Ralli M, Modica DM, et al. The Role of Probiotics in Chronic Rhinosinusitis Treatment: An Update of the Current Literature. Healthcare (Basel) 2021; 9.</a></li><li><a class="nounderline abstract_t">Jin AJ, Chin CJ. Is acupuncture effective in reducing overall symptomatology in chronic rhinosinusitis? Laryngoscope 2019; 129:1727.</a></li><li><a class="nounderline abstract_t">Schmale IL, Nimmagadda SV, Ravikumar S, et al. Ayurvedic medicine for the treatment of chronic rhinosinusitis: a systematic review of randomized and non-randomized trials. J Complement Integr Med 2023; 20:675.</a></li><li><a class="nounderline abstract_t">Nimmagadda SV, Schmale IL, Man LX. Crenotherapy as a Complementary and Integrative Treatment for Chronic Rhinosinusitis: A Systematic Review and Discussion of Current Evidence Limitations. Am J Rhinol Allergy 2022; 36:529.</a></li><li><a class="nounderline abstract_t">Head K, Chong LY, Piromchai P, et al. Systemic and topical antibiotics for chronic rhinosinusitis. Cochrane Database Syst Rev 2016; 4:CD011994.</a></li><li><a class="nounderline abstract_t">Ozturk F, Bakirtas A, Ileri F, Turktas I. Efficacy and tolerability of systemic methylprednisolone in children and adolescents with chronic rhinosinusitis: a double-blind, placebo-controlled randomized trial. J Allergy Clin Immunol 2011; 128:348.</a></li><li><a class="nounderline abstract_t">Snidvongs K, Sangubol M, Poachanukoon O. Pediatric Versus Adult Chronic Rhinosinusitis. Curr Allergy Asthma Rep 2020; 20:29.</a></li><li><a class="nounderline abstract_t">Brietzke SE, Brigger MT. Adenoidectomy outcomes in pediatric rhinosinusitis: a meta-analysis. Int J Pediatr Otorhinolaryngol 2008; 72:1541.</a></li><li><a class="nounderline abstract_t">Bettadahalli V, Chakravarti A. Post-adenoidectomy quality of life in children with refractory chronic rhinosinusitis. J Laryngol Otol 2017; 131:773.</a></li><li><a class="nounderline abstract_t">Brietzke SE, Shin JJ, Choi S, et al. Clinical consensus statement: pediatric chronic rhinosinusitis. Otolaryngol Head Neck Surg 2014; 151:542.</a></li><li><a class="nounderline abstract_t">Makary CA, Ramadan HH. The role of sinus surgery in children. Laryngoscope 2013; 123:1348.</a></li><li><a class="nounderline abstract_t">Ramadan HH, McLaughlin K, Josephson G, et al. Balloon catheter sinuplasty in young children. Am J Rhinol Allergy 2010; 24:e54.</a></li><li><a class="nounderline abstract_t">Thottam PJ, Haupert M, Saraiya S, et al. Functional endoscopic sinus surgery (FESS) alone versus balloon catheter sinuplasty (BCS) and ethmoidectomy: a comparative outcome analysis in pediatric chronic rhinosinusitis. Int J Pediatr Otorhinolaryngol 2012; 76:1355.</a></li><li><a class="nounderline abstract_t">Sedaghat AR, Cunningham MJ. Does balloon catheter sinuplasty have a role in the surgical management of pediatric sinus disease? Laryngoscope 2011; 121:2053.</a></li><li><a class="nounderline abstract_t">Patel VA, O'Brien DC, Ramadan J, Carr MM. Balloon Catheter Dilation in Pediatric Chronic Rhinosinusitis: A Meta-analysis. Am J Rhinol Allergy 2020; 34:694.</a></li><li><a class="nounderline abstract_t">Ge M, Liu DH, Ference EH. Pediatric chronic sinusitis: diagnosis and management. Curr Opin Otolaryngol Head Neck Surg 2022; 30:68.</a></li><li><a class="nounderline abstract_t">Lal D, Jategaonkar AA, Borish L, et al. Management of rhinosinusitis during pregnancy: systematic review and expert panel recommendations. Rhinology 2016; 54:99.</a></li><li><a class="nounderline abstract_t">Seys SF, Hellings PW, Alobid I, et al. Chronic Rhinosinusitis Outcome Registry (CHRINOSOR): Establishment of an International Outcome Registry Driven by mHealth Technology. J Allergy Clin Immunol Pract 2023; 11:431.</a></li></ol></div><div id="topicVersionRevision">Topic 121194 Version 4.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26569006" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Identifying the most important outcomes for systematic reviews of interventions for rhinosinusitis in adults: working with Patients, Public and Practitioners.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33236525" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : International consensus statement on allergy and rhinology: rhinosinusitis 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32226949" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Executive summary of EPOS 2020 including integrated care pathways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10229979" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Nasal douching as a valuable adjunct in the management of chronic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28972988" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Orbital complications of paranasal sinusitis in Taiwan, 1988 through 2015: Acute ophthalmological manifestations, diagnosis, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29536253" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Simultaneous treatment of intracranial complications of paranasal sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33831391" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Septic cavernous sinus thrombosis: A review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35720767" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Optimal Device and Regimen of Nasal Saline Treatment for Sinonasal Diseases: Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18025315" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Nasal saline for chronic sinonasal symptoms: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27115217" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Intranasal steroids versus placebo or no intervention for chronic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15564850" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A comparative study of three methods of nasal irrigation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29774747" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Hypertonic Saline Versus Isotonic Saline Nasal Irrigation: Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20824637" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The clinical significance of nasal irrigation bottle contamination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18284857" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Baby shampoo nasal irrigations for the symptomatic post-functional endoscopic sinus surgery patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25256029" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Diagnosis and management of rhinosinusitis: a practice parameter update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23710959" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Sinus surgery and delivery method influence the effectiveness of topical corticosteroids for chronic rhinosinusitis: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30477309" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : NAVIGATE I: Randomized, Placebo-Controlled, Double-Blind Trial of the Exhalation Delivery System With Fluticasone for Chronic Rhinosinusitis With Nasal Polyps.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29928924" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : NAVIGATE II: Randomized, double-blind trial of the exhalation delivery system with fluticasone for nasal polyposis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25483598" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Effect of budesonide transnasal nebulization in patients with eosinophilic chronic rhinosinusitis with nasal polyps.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19909862" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Local drug delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36116748" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Review of evidence supporting the use of nasal corticosteroid irrigation for chronic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21833974" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Topical steroid for chronic rhinosinusitis without polyps.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33300989" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Evaluation of Smoking as a Modifying Factor in Chronic Rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36895147" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Association between laryngopharyngeal reflux, gastroesophageal reflux and recalcitrant chronic rhinosinusitis: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33384837" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Odontogenic maxillary sinusitis: A comprehensive review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30989083" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Definition and management of odontogenic maxillary sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30036413" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Antibiotics, steroids, and combination therapy in chronic rhinosinusitis without nasal polyps in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27863163" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Surgical therapy vs continued medical therapy for medically refractory chronic rhinosinusitis: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34510786" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Endoscopic sinus surgery for chronic rhinosinusitis: 22-item Sino-Nasal Outcome Test 5-year results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31207172" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Long-term outcomes of endoscopic sinus surgery in the management of adult chronic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10388881" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Long-term impact of functional endoscopic sinus surgery on asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23686815" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Long-term results of endoscopic sinus surgery-oriented treatment for chronic rhinosinusitis with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23818462" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A systematic review and meta-analysis of asthma outcomes following endoscopic sinus surgery for chronic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23818462" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A systematic review and meta-analysis of asthma outcomes following endoscopic sinus surgery for chronic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23818462" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A systematic review and meta-analysis of asthma outcomes following endoscopic sinus surgery for chronic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22550039" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Effect of steroid-releasing sinus implants on postoperative medical and surgical interventions: an efficacy meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22287473" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Management of early nasal polyposis using a steroid-impregnated nasal dressing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24119605" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Systemic effects and safety of triamcinolone-impregnated nasal packing after endoscopic sinus surgery: a randomized, double-blinded, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35703383" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Balloon Sinus Dilation Versus Functional Endoscopic Sinus Surgery for Chronic Rhinosinusitis: Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21735433" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Functional endoscopic balloon dilation of sinus ostia for chronic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19419611" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Transantral, endoscopically guided balloon dilatation of the ostiomeatal complex for chronic rhinosinusitis under local anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18707993" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Long-term outcome analysis of balloon catheter sinusotomy: two-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23920419" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Standalone balloon dilation versus sinus surgery for chronic rhinosinusitis: a prospective, multicenter, randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24823902" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Standalone balloon dilation versus sinus surgery for chronic rhinosinusitis: a prospective, multicenter, randomized, controlled trial with 1-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29389303" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Clinical Consensus Statement: Balloon Dilation of the Sinuses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9768318" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Recirculation of mucus as a cause of persistent sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11801976" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Top 10 reasons for endoscopic maxillary sinus surgery failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17981318" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Nasal and sinus endoscopy for medical management of resistant rhinosinusitis, including postsurgical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9339809" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Recirculation of mucus via accessory ostia causing chronic maxillary sinus disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9127518" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Endoscopic view of recirculation phenomenon of the maxillary sinus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8714416" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Endoscopic view of the recirculation phenomenon of sphenoid sinus drainage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12610908" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Iatrogenic maxillary sinus recirculation and beyond.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24657331" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Diagnostic criteria for a curable form of chronic rhinosinusitis: the mucous recirculation syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34740749" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The immunomodulatory effects of macrolide antibiotics in respiratory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27809411" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Long-term low-dose macrolides for chronic rhinosinusitis in adults - a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16467702" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : A double-blind, randomized, placebo-controlled trial of macrolide in the treatment of chronic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22801017" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Efficacy of Chinese herbal medicine compared with a macrolide in the treatment of chronic rhinosinusitis without nasal polyps.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22185725" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Comparison of efficacy of mometasone furoate versus clarithromycin in the treatment of chronic rhinosinusitis without nasal polyps in Chinese adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31838920" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A 10-Year Follow-Up of a Randomized Prospective Study of 2 Treatments for Chronic Rhinosinusitis Without Nasal Polyps and Investigation of the Impact of Gastroeosophageal Reflux Disease in the Resistance to Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31036048" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Clarithromycin and endoscopic sinus surgery for adults with chronic rhinosinusitis with and without nasal polyps: study protocol for the MACRO randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31403137" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Optimising trial outcomes and patient retention for the MACRO trial for chronic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31014344" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Expert panel process to optimise the design of a randomised controlled trial in chronic rhinosinusitis (the MACRO programme).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33527730" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Benefits of biologic therapy administered for asthma on co-existent chronic rhinosinusitis: A real-world study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34474711" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Impact of type 2 targeting biologics on acute exacerbations of chronic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23587334" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma&amp;Immunology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27639939" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Heterogeneous inflammatory patterns in chronic rhinosinusitis without nasal polyps in Chicago, Illinois.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33326802" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Mechanisms and biomarkers of inflammatory endotypes in chronic rhinosinusitis without nasal polyps.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34473358" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Endotypes of chronic rhinosinusitis: Relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36454862" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Chinese herbal therapy in the management of rhinosinusitis-A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30199594" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Topical and systemic antifungal therapy for chronic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34946441" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : The Role of Probiotics in Chronic Rhinosinusitis Treatment: An Update of the Current Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30515831" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Is acupuncture effective in reducing overall symptomatology in chronic rhinosinusitis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36800361" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Ayurvedic medicine for the treatment of chronic rhinosinusitis: a systematic review of randomized and non-randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35195469" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Crenotherapy as a Complementary and Integrative Treatment for Chronic Rhinosinusitis: A Systematic Review and Discussion of Current Evidence Limitations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27113482" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Systemic and topical antibiotics for chronic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21624649" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Efficacy and tolerability of systemic methylprednisolone in children and adolescents with chronic rhinosinusitis: a double-blind, placebo-controlled randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32506185" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Pediatric Versus Adult Chronic Rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18723228" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Adenoidectomy outcomes in pediatric rhinosinusitis: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28716161" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Post-adenoidectomy quality of life in children with refractory chronic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25274375" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Clinical consensus statement: pediatric chronic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23361382" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : The role of sinus surgery in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20109327" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Balloon catheter sinuplasty in young children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22770596" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Functional endoscopic sinus surgery (FESS) alone versus balloon catheter sinuplasty (BCS) and ethmoidectomy: a comparative outcome analysis in pediatric chronic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21952904" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Does balloon catheter sinuplasty have a role in the surgical management of pediatric sinus disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32264691" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Balloon Catheter Dilation in Pediatric Chronic Rhinosinusitis: A Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34958324" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Pediatric chronic sinusitis: diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26800862" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Management of rhinosinusitis during pregnancy: systematic review and expert panel recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36272718" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Chronic Rhinosinusitis Outcome Registry (CHRINOSOR): Establishment of an International Outcome Registry Driven by mHealth Technology.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
